ADMA Biologics ups FY24 revenue view to over $330M from $320M, consensus $315.3M

Raises FY24 adjusted EBITDA view to over $90M from $85M. Raises FY25 revenue view to over $380M from $370M. Sees FY25 adjusted EBITDA over $140M. Grossman continued, “In conjunction with the ongoing expansion of our commercial product portfolio, we look forward to advancing new growth initiatives, including innovations to ADMA‘s manufacturing processes and potential yield enhancement, as well as progress with our preclinical S. pneumonia pipeline program. Based upon current market factors, we anticipate 2024 being defined by top-tier revenue and earnings growth, cash generation, and the further de-risking of growth initiatives which, if successful, we believe have the potential to significantly impact ADMA’s peak revenue and earnings targets. We believe our proven internal R&D capabilities, broad intellectual property estate and successful establishment of our innovative commercial model position the Company for enduring success in the future.”